“Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis”, J of Skin, vol. 2, no. S1, p. S1, Feb. 2018, doi: 10.25251/skin.2.supp.1.